350 related articles for article (PubMed ID: 29160598)
1. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
Inoue T; Nishimura A; Sasai K; Kitagawa T
Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):583-91. PubMed ID: 26035186
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
Boulenger JP; Loft H; Olsen CK
Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
[TBL] [Abstract][Full Text] [Related]
6. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
[TBL] [Abstract][Full Text] [Related]
7. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
Wang G; Gislum M; Filippov G; Montgomery S
Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
[TBL] [Abstract][Full Text] [Related]
8. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.
Liebowitz MR; Careri J; Blatt K; Draine A; Morita J; Moran M; Hanover R
Depress Anxiety; 2017 Dec; 34(12):1164-1172. PubMed ID: 29166552
[TBL] [Abstract][Full Text] [Related]
9. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
[TBL] [Abstract][Full Text] [Related]
12. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
Baldwin DS; Chrones L; Florea I; Nielsen R; Nomikos GG; Palo W; Reines E
J Psychopharmacol; 2016 Mar; 30(3):242-52. PubMed ID: 26864543
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study.
Wang J; Liu XF; Feng C; Bao Q; Fu HR
Int J Psychiatry Clin Pract; 2019 Nov; 23(4):245-250. PubMed ID: 29113521
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Croft HA; Pomara N; Gommoll C; Chen D; Nunez R; Mathews M
J Clin Psychiatry; 2014 Nov; 75(11):e1291-8. PubMed ID: 25470094
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies.
Mattingly GW; Necking O; Schmidt SN; Reines E; Ren H
Curr Med Res Opin; 2023 Apr; 39(4):613-619. PubMed ID: 36884024
[TBL] [Abstract][Full Text] [Related]
16. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Alam MY; Jacobsen PL; Chen Y; Serenko M; Mahableshwarkar AR
Int Clin Psychopharmacol; 2014 Jan; 29(1):36-44. PubMed ID: 24169027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
